🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareAlcohol metabolism changes on semaglutide — emerging data

Alcohol metabolism changes on semaglutide — emerging data

NeuroNate Thu, Jun 4, 2026 at 10:31 AM 21 replies 364 viewsPage 1 of 5
NeuroNate
Senior Member
2,890
16,789
Dec 2023
Chicago, IL
Jun 4, 2026 at 10:31 AM#1

Putting this up for argument rather than for agreement. I have read it twice and I am still not certain what it supports.

Steady state is the thing most people miss. The terminal half-life is about a week, so every dose step takes four to five weeks to fully express itself. Judging a step at day ten is judging the ascent, not the plateau, and it is the single commonest reason people escalate before they needed to.

Where I think it is weakest: the population was selected and supported in ways a real cohort is not, so I would read the effect size as a ceiling rather than an expectation.

The narrow version of the question is whether anyone has held at a sub-maximal dose long term and kept the result, or whether the maintenance data only exists at 2.4mg. Happy to be told the question itself is wrong.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
13 8jason_paloalto, Dr.LeslieOBGYN, MikeNYC_runner and 10 others
Reply Quote Save Share Report
Dr.GastroMayo
VIP Member
2,345
13,456
Jan 2024
Mayo Clinic, MN
Jun 4, 2026 at 10:34 AM#2
NeuroNate said:
Steady state is the thing most people miss.

Agreed, though "tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.

Last edited: Jun 4, 2026 at 3:34 PM
12 7VendorMark, COA_Karl, MikeFit_NJ and 9 others
Reply Quote Save Share Report
InsuranceTom
Senior Member
1,345
7,890
Mar 2024
Connecticut
Jun 4, 2026 at 10:37 AM#3
NeuroNate said:
Steady state is the thing most people miss.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

Ask again with the specifics and you will get a better answer than this one.

11 6Dr.ReproEndo, lucas_SP_BR, lisa_labSD and 8 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
VanRx_Mike
Member
678
2,890
May 2024
Vancouver, CA
Jun 4, 2026 at 10:41 AM#4

Answering the narrow version, because the broad one does not have a single answer. The mechanism that matters here is not stomach emptying, it is central. GLP-1 receptor agonism in the arcuate nucleus stimulates POMC neurons and suppresses AgRP/NPY signalling, which is why the effect is appetite and food salience rather than physical fullness. Delayed gastric emptying largely tachyphylaxes over the first months; the appetite effect does not.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

10 5Dr.Martinez, mike_mod, SarahChen_PharmD and 7 others
Reply Quote Save Share Report
MikeNYC_runner
Member
378
1,678
Jul 2024
New York, NY
Jun 4, 2026 at 10:59 AM#5
Dr.GastroMayo said:
Agreed, though "tolerable" needs defining.

All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

Last edited: Jun 4, 2026 at 12:59 PM
9 4MASHdoc_SA, GenomicsKate, Dr.ObesityMed and 6 others
Reply Quote Save Share Report
1235

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register